These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

637 related items for PubMed ID: 31692283

  • 1. Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients.
    Ding Y, Zhang L, Guo L, Wu C, Zhou J, Zhou Y, Ma J, Li X, Ji P, Wang M, Zhu W, Shi C, Li S, Wu W, Zhu W, Xiao D, Fu C, He Q, Sun R, Mao X, Lizaso A, Li B, Han-Zhang H, Zhang Z.
    Thorac Cancer; 2020 Jan; 11(1):103-112. PubMed ID: 31692283
    [Abstract] [Full Text] [Related]

  • 2. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing.
    Zhang Y, Chang L, Yang Y, Fang W, Guan Y, Wu A, Hong S, Zhou H, Chen G, Chen X, Zhao S, Zheng Q, Pan H, Zhang L, Long H, Yang H, Wang X, Wen Z, Wang J, Yang H, Xia X, Zhao Y, Hou X, Ma Y, Zhou T, Zhang Z, Zhan J, Huang Y, Zhao H, Zhou N, Yi X, Zhang L.
    Mol Cancer; 2019 Jan 09; 18(1):7. PubMed ID: 30626401
    [Abstract] [Full Text] [Related]

  • 3. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
    Yang K, Wu Y.
    BMC Cancer; 2021 Feb 06; 21(1):128. PubMed ID: 33549049
    [Abstract] [Full Text] [Related]

  • 4. Whole-Exome Sequencing and Experimental Validation Unveil the Roles of TMEM229A Q200del Mutation in Lung Adenocarcinoma.
    Liang YX, Xie YP, Yu HM, Zhu WJ, Yin CY, Dong ZH, Zhang XL.
    Clin Respir J; 2024 Aug 06; 18(8):e70006. PubMed ID: 39188060
    [Abstract] [Full Text] [Related]

  • 5. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
    Meng F, Zhang L, Ren Y, Ma Q.
    J Cell Physiol; 2019 Jul 06; 234(7):10918-10925. PubMed ID: 30549039
    [Abstract] [Full Text] [Related]

  • 6. Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single-cell transcriptomic analysis: Implications for distinct immunotherapy outcomes.
    Fang X, Li D, Wan S, Hu J, Zhang P, Jie D, Chen L, Jiang G, Song N.
    J Gene Med; 2024 Jun 06; 26(6):e3694. PubMed ID: 38847309
    [Abstract] [Full Text] [Related]

  • 7. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
    Ghosh M, Mukhopadhyay M, Das C, Chatterjee S, Naskar BG.
    J Cancer Res Ther; 2021 Jun 06; 17(6):1389-1396. PubMed ID: 34916369
    [Abstract] [Full Text] [Related]

  • 8. Differential MUC22 expression by epigenetic alterations in human lung squamous cell carcinoma and adenocarcinoma.
    Lin S, Tian C, Li J, Liu B, Ma T, Chen K, Gong W, Wang JM, Huang J.
    Oncol Rep; 2021 May 06; 45(5):. PubMed ID: 33786615
    [Abstract] [Full Text] [Related]

  • 9. Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients.
    Sun Y, Yu X, Shi X, Hong W, Zhao J, Shi L.
    World J Surg Oncol; 2014 May 19; 12():148. PubMed ID: 24885205
    [Abstract] [Full Text] [Related]

  • 10. Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer.
    Yu H, Pang Z, Li G, Gu T.
    J Clin Lab Anal; 2021 Feb 19; 35(2):e23588. PubMed ID: 32965722
    [Abstract] [Full Text] [Related]

  • 11. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
    Cruz-Rico G, Avilés-Salas A, Popa-Navarro X, Lara-Mejía L, Catalán R, Sánchez-Reyes R, López-Sánchez D, Cabrera-Miranda L, Aquiles Maldonado-Martínez H, Samtani-Bassarmal S, Arrieta O.
    Pathol Oncol Res; 2021 Feb 19; 27():597499. PubMed ID: 34257548
    [Abstract] [Full Text] [Related]

  • 12. System analysis of FHIT in LUAD and LUSC: The expression, prognosis, gene regulation network, and regulation targets.
    Situ Y, Gao R, Lei L, Deng L, Xu Q, Shao Z.
    Int J Biol Markers; 2022 Jun 19; 37(2):158-169. PubMed ID: 35254116
    [Abstract] [Full Text] [Related]

  • 13. Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape.
    Xia W, Mao W, Chen R, Lu R, Liu F, He Y, Wang S, Li X, Zheng M.
    Med Sci Monit; 2019 Nov 20; 25():8764-8776. PubMed ID: 31746315
    [Abstract] [Full Text] [Related]

  • 14. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
    Chan AW, Chau SL, Tong JH, Chow C, Kwan JSH, Chung LY, Lung RW, Tong CY, Tin EK, Law PP, Law WT, Ng CSH, Wan IYP, Mok TSK, To KF.
    J Thorac Oncol; 2019 Jul 20; 14(7):1213-1222. PubMed ID: 30978501
    [Abstract] [Full Text] [Related]

  • 15. Association of TOP2A and ADH1B with lipid levels and prognosis in patients with lung adenocarcinoma and squamous cell carcinoma.
    Yin D, Zhang Y, Li H, Cheng L.
    Clin Respir J; 2023 Dec 20; 17(12):1301-1315. PubMed ID: 37985446
    [Abstract] [Full Text] [Related]

  • 16. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
    Hou G, Lu Z, Bi Y, Deng J, Yang X.
    Med Oncol; 2022 Feb 12; 39(5):51. PubMed ID: 35150321
    [Abstract] [Full Text] [Related]

  • 17. Molecular subtypes based on DNA methylation predict prognosis in lung squamous cell carcinoma.
    Li XS, Nie KC, Zheng ZH, Zhou RS, Huang YS, Ye ZJ, He F, Tang Y.
    BMC Cancer; 2021 Jan 23; 21(1):96. PubMed ID: 33485313
    [Abstract] [Full Text] [Related]

  • 18. Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancer.
    Rice SJ, Liu X, Hyland V, Liu Z, Belani CP.
    Lung Cancer; 2020 Mar 23; 141():97-100. PubMed ID: 31986371
    [Abstract] [Full Text] [Related]

  • 19. Differential prognostic impact and potential molecular mechanisms of PCDHGA12 expression in lung adenocarcinoma and squamous cell carcinoma.
    Xu X, Zhang J, Yao T, Zhao X, Wu Q, Lu C, Guo X, Xie S, Qiu L, Bi R, Xue H.
    Int Immunopharmacol; 2024 Sep 30; 139():112727. PubMed ID: 39067405
    [Abstract] [Full Text] [Related]

  • 20. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.
    Ning J, Jiang S, Li X, Wang Y, Deng X, Zhang Z, He L, Wang D, Jiang Y.
    BMC Pulm Med; 2021 Jun 10; 21(1):199. PubMed ID: 34112123
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.